Provincial formulary updates

Ontario Update   The Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (Formulary) has been updated and becomes effective April 27, 2017. The highlights are noted below: New Limited Use (LU) products: Entresto (sacubitril & valsartan) for the treatment of heart failure (Novartis) Creon Minimicrospheres (pancrelipase) as replacement therapy for pancreatic insufficiency (BGP Pharma) Product with revised Limited Use criteria: Brilinta (ticagrelor) for treatment of myocardial infarctions or unstable…

BC Update   The British Columbia Pharmacare newsletter was published on February 27, 2017   See British Columbia's Newsletter   As noted in the newsletter, for the pricing period starting April 1, 2017, the maximum price that suppliers can charge for generic LCA drugs will continue as: 20% of the equivalent brand product’s list price for oral solids 35% of the equivalent brand product’s list price for drugs available in…

The pCPA has completed negotiations with 3 manufacturers of drugs used to treat Hepatitis C   The pan-Canadian Pharmaceutical Alliance (pCPA), in its first stand-alone statement, announced on February 21, 2017 that they have successfully negotiated agreements with Gilead, Merck, and Bristol Myers Squibb. There is one notable absence from this list - that of the 4th manufacturer of hepatitis C drugs, Abbvie who manufactures Holkira and Technivie.   These…

Alberta Update   The Alberta Drug Benefit List (DBL) / Alberta Human Services Drug Benefit Supplement has been updated and becomes effective March 1, 2017.   See Alberta's Drug Benefit List   See Alberta's Human Services Drug Benefit Supplement   To receive updates similar to this one please be sure to sign up for Market Access Signals, our free e-mail newsletter service.

Ontario Update   Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (Formulary) has been updated and becomes effective February 28, 2017.   See Ontario's Drug Benefit Formulary   New Single Source Drug Products   Daklinza (daclatasvir) 30mg, 60mg Tab (BMS) Epclusa (sofosbuvir / velpatasvir) 400mg/100mg Tab (GIL) Sunvepra (asunaprevir) 100mg Tab (BMS) Zepatier (elbasvir / grazoprevir) 50mg/100mg Tab (MEK)   Transition from Exceptional Access Program (EAP) to Limited Use…